Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine and Subcutaneous Rituximab in Elderly Aggressive B-cell Lymphoma
NCT01686321Phase 2Completed
- Sponsor
- Georg-August-Universität Göttingen
- Start
- Jul 2012
- Primary completion
- Aug 2018
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine and rituximab in aggressive B-cell lymphoma, sponsored by Georg-August-Universität Göttingen. Primary endpoints: Progression-free survival at 2 years, Adverse events and 3 more. Started Jul 2012; status: completed.
02
Drugs
bendamustinerituximab
03
Conditions
aggressive B-cell lymphoma
Beyond the preview
Go deeper on NCT01686321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01686321.